Demetrius Klee Lopes

In 2019, Lopes published a preliminary study on usage of the pipeline embolization device to treat small to medium-sized intracranial aneurysms, and has also demonstrated its safety and efficacy for patients under 22 years old. Later that year, Lopes also published research results demonstrating the safety and efficacy of transvenous embolization for treating arteriovenous malformations.

In July 2018, Lopes joined Advocate Health Care as co-director of the stroke program.

In 2015, Lopes published articles confirming that the use of endovascular therapy for ischemic stroke improves patient outcomes.

In 2015, along with Elad Levy, Lopes performed research resulting in paradigm shifts in the treatment of cerebrovascular diseases, including being the US Interventional Principal Investigator for the SWIFT PRIME trials. Lopes also conducted research on the efficacy and safety of endovascular thrombectomy in 2018.

In 2013, Lopes founded the nonprofit Cure4Stroke Foundation that aims to raise stroke awareness and celebrate stroke survivors.

In 2001, Lopes joined Rush University Medical Center. In May 2006, he was voted Chicago's "Dr. McDreamy" by the readers of the Chicago Tribune.

Demetrius Klee Lopes (born March 19, 1970) is a cerebrovascular neurosurgeon specializing in neuroendovascular therapy. At Advocate Health, he serves as medical director of the cerebrovascular and neuroendovascular program and is co-director of their stroke program.

Born in March 19, 1970, Lopes lived in Brazil until 1993. He began his medical education in 1987 at Federal University of Rio Grande do Sul. After completing his doctorate in medicine in 1993, he completed his residency and fellowship at State University of New York at Buffalo.